Anna Tomczyk
Partner | New York
Anna Tomczyk

Anna Tomczyk represents issuers and underwriters on public and private securities offerings, including initial public offerings, follow-on offerings and secondary public offerings, as well as Rule 144A and Regulation S offerings. Ms. Tomczyk also advises companies on mergers and acquisitions, corporate governance, periodic reporting and securities regulation and compliance. She counsels clients from a wide variety of industries, including life sciences, financial services and retail. 

  • BioAtla, Inc. (Nasdaq: “BCAB”) in its US$189 million initial public offering (with J.P. Morgan, Jefferies and Credit Suisse acting as joint book-running managers).
  • VIA optronics AG, a leading supplier of enhanced display solutions, in its US$93.75 million cross-border initial public offering and listing on the NYSE.
  • Acacia Research Corporation (Nasdaq: "ACTG") in connection with its strategic partnership with Starboard Value, consisting of a financing providing Acacia with access to up to US$400 million of new capital for strategic investments and acquisitions.
  • B&G Foods in connection with its registered public offering of US$550 million in aggregate principal amount of 5.25% senior notes due 2027.
  • Zyla Life Sciences on securities law aspects in its merger with Assertio Therapeutics, Inc.
  • Sales Agents in multiple At-The-Market offerings by Inovio Pharmaceuticals, Inc., a clinical stage company developing active DNA immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases.
  • OraSure Technologies, Inc. in its US$95 million public offering of common stock.
  • The underwriters in connection with Repro Med Systems, Inc. d/b/a KORU Medical Systems (Nasdaq: KRMD)’s US$25 million public offering of common stock.
  • Cowen and Company, as underwriter, in the US$97 million initial public offering of Boston Omaha Corporation. 
  • Minerva Neurosciences Inc. in its US$32 million initial public offering.
  • Piper Jaffray, as managing underwriter, in the US$40 million initial public offering of Tengion Inc.
  • Cowen and Company, as lead underwriter, in a US$55 million follow-on offering for TherapeuticsMD, Inc.
  • Cowen and Company, as lead underwriter, in US$15 million and US$30 million follow-on offerings for Trillium Therapeutics.
  • Cowen and Company, as sales agent, in at-the-market offerings for Amicus Therapeutics, Boston Omaha Corporation, Kempharm Inc., and Trillium Therapeutics Inc. 
  • Stifel, Nicolaus & Company, as lead underwriter, in a US$30 million follow-on offering for TherapeuticsMD, Inc.
  • RBC Capital Markets LLC, as lead underwriter, in a US$25 million follow-on offering for Kempharm Inc.
  • RBC Capital Markets LLC, as sales agent, in an at-the-market offering for Kempharm Inc.
  • The initial purchasers in a US$225 million offering of convertible senior notes for Amicus Therapeutics.
  • Anterios Inc. on its sale to Allergan.
  • A fishing supply company in its US$330 million high yield note offering.
  • Rexnord Corporation, in its US$500 million high yield note offering.
  • A mass customization conglomerate in its US$400 million senior note offering.
  • The underwriters, including Credit Suisse, Deutsche Bank, Goldman Sachs, J.P. Morgan, Morgan Stanley, UBS and Wells Fargo, in follow-on offerings of common stock and preferred stock of numerous international shipping and oil & gas companies, including Baltic Trading, Box Ships, Costamare, Dryships, Excel Maritime, GasLog, Ocean Rig, Safe Bulkers and Scorpio Bulkers. 
  • Jefferies, on securities law aspects of its US$10 billion merger of equals with Leucadia National Corporation. 

Includes matters handled at Dechert or prior to joining the firm.

Services Industries
    • University of Rochester, B.A., 2005
    • Fordham University School of Law, J.D., 2008
    • New York
    • Member, Capital Markets Editorial Advisory Board for 2023, Law360